Ahmedabad-based biopharma startup Lamark Biotech has raised ₹6.5 crore in a Pre-Series A funding round led by IAN Group, including the IAN Alpha Fund. The round also saw strategic backing from BioAngels and prominent individual investors such as Vinayender Tulla, Nita Roy, and Venkataraman KNK. According to the company, domain experts from IAN’s angel network played a key role in leading the round.
Founded in 2018 by Vaibhav Bhatia, Lamark Biotech is on a mission to revolutionize drug delivery for chronic and life-altering conditions. The startup is developing thermostable biologics—proteins that retain their potency without the need for cold storage—an innovation that could have significant global impact, particularly in regions where access to refrigeration is limited.
The fresh capital will be used to advance its lead product, InsulinStrong, a heat-stable insulin targeting India’s ₹4,000 crore insulin market. The company also plans to scale up its proprietary ProteoStrong platform, which helps stabilize fragile protein-based drugs like insulin, monoclonal antibodies, and enzymes without altering their structure.
“We are focused on creating a new class of temperature-resilient biologics that can withstand extreme conditions. This is crucial for reaching underserved populations, where cold chain infrastructure is often inadequate,” said founder Vaibhav Bhatia.
The company, which earlier raised a seed round of $41.3K backed by VIT-TBI, is currently leveraging the deep R&D ecosystem of Venture Center and NCL Innovation in Pune. Its sights are set not just on India but also on Southeast Asia and the UAE.
Over the next 24 months, Lamark plans to file international patents, initiate early-stage clinical trials, and build strategic alliances with global pharma companies, Contract Development and Manufacturing Organizations (CDMOs), and international health agencies.
With a focus on affordability, accessibility, and innovation, Lamark Biotech is one to watch in the evolving landscape of next-gen biologics.
